NeoGenomics, Inc. (NEO)
Automate Your Wheel Strategy on NEO
With Tiblio's Option Bot, you can configure your own wheel strategy including NEO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NEO
- Rev/Share 5.2786
- Book/Share 6.9736
- PB 0.2114
- Debt/Equity 0.6809
- CurrentRatio 2.052
- ROIC -0.0569
- MktCap 189696423.0
- FreeCF/Share -0.2541
- PFCF -5.8612
- PE -2.4199
- Debt/Assets 0.3777
- DivYield 0
- ROE -0.0859
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 5
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | NEO | Guggenheim | -- | Neutral | -- | -- | May 15, 2025 |
| Downgrade | NEO | Leerink Partners | Outperform | Market Perform | -- | $9 | April 30, 2025 |
| Downgrade | NEO | The Benchmark Company | Buy | Hold | -- | -- | Jan. 13, 2025 |
| Initiation | NEO | Jefferies | -- | Buy | -- | $22 | Dec. 10, 2024 |
News
NeoGenomics Launches c-MET CDx Assay to Guide Treatment Decisions for Advanced Non-Small Cell Lung Cancer
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the commercial launch of c-MET CDx for NSCLC, its c-MET companion diagnostic immunohistochemistry (IHC) assay.
Read More
It's Not Too Late to Jump on These Under-the-Radar Momentum Plays
Published: May 06, 2025 by: MarketBeat
Sentiment: Positive
Those subscribing to a momentum investing strategy tend to believe that stocks experiencing price increases tend to rally, so long as both internal and external conditions don't change. Of course, no rally can continue forever, so investors may measure momentum across different timeframes.
Read More
NeoGenomics Q1 Earnings: The Stock Price Drop Is A Gift (Rating Upgrade)
Published: April 30, 2025 by: Seeking Alpha
Sentiment: Positive
NeoGenomics' recent 32.23% stock price decline post-Q1 earnings miss is seen as a buying opportunity due to overreaction and long-term growth potential. Despite a slight revenue miss, the company's long-term growth remains strong, with a 10-year CAGR of 23.27% and a positive future outlook. The company's acquisition of Pathline and raised FY 2025 guidance further support its growth and undervaluation, justifying a buy rating.
Read More
NeoGenomics, Inc (NEO) Q1 2025 Earnings Call Transcript
Published: April 29, 2025 by: Seeking Alpha
Sentiment: Neutral
NeoGenomics, Inc (NASDAQ:NEO ) Q1 2025 Earnings Conference Call April 29, 2025 8:30 AM ET Company Participants Kendra Sweeney - Vice President, Investor Relations and ESG Tony Zook - Chief Executive Officer Warren Stone - President and Chief Operating Officer Andrew Lukowiak - Chief Innovation Officer Jeffrey Sherman - Chief Financial Officer Kareem Saad - Head, Strategy and Transformation Ali Olivo - Executive Vice President, General Counsel & Business Development Dr. Nate Montgomery - Vice President, Medical Services Conference Call Participants Andrew Brackman - William Blair Dan Brennan - TD Cowen Tejas Savant - Morgan Stanley Mike Matson - Needham …
Read More
NeoGenomics (NEO) Reports Break-Even Earnings for Q1
Published: April 29, 2025 by: Zacks Investment Research
Sentiment: Neutral
NeoGenomics (NEO) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to loss of $0.02 per share a year ago.
Read More
NeoGenomics Reports First Quarter 2025 Results
Published: April 29, 2025 by: Business Wire
Sentiment: Neutral
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its first-quarter results for the period ended March 31, 2025.
Read More
NeoGenomics: Decent Fundamentals, But Still Overvalued
Published: February 28, 2025 by: Seeking Alpha
Sentiment: Negative
NeoGenomics is rated a Hold due to the intrinsic value being lower than the current price, and the company's negative net income and FCF. Despite revenue growth and increasing clinical volume, NeoGenomics missed revenue estimates, causing a 15.50% drop in the stock price. NeoGenomics shows promising long-term growth potential with rising cancer cases and improving ROIC, but negative profitability is a concern.
Read More
NeoGenomics, Inc (NEO) Q4 2024 Earnings Call Transcript
Published: February 18, 2025 by: Seeking Alpha
Sentiment: Neutral
NeoGenomics, Inc (NASDAQ:NEO ) Q4 2024 Earnings Conference Call February 18, 2025 8:30 AM ET Company Participants Kendra Sweeney - Vice President, Investor Relations and ESG Chris Smith - Chief Executive Officer Warren Stone - Chief Commercial Officer Andrew Lukowiak - Chief Innovation Officer Jeffrey Sherman - Chief Financial Officer Kareem Saad - Head, Strategy and Transformation Nate Montgomery - Vice President, Medical Services Conference Call Participants Andrew Brackman - William Blair Puneet Souda - SVB Leerink Jack Slevin - Jefferies Mason Carrico - Stephens Tejas Savant - Morgan Stanley Vivian Bais - BTIG Prashant Kota - Goldman Sachs Dan …
Read More
About NeoGenomics, Inc. (NEO)
- IPO Date 2004-03-16
- Website https://www.neogenomics.com
- Industry Medical - Diagnostics & Research
- CEO Mr. Anthony P. Zook
- Employees 2200